Top Markets
#1 Black Phoenix Black Phoenix +733.12%
#2 MiL.k Alliance MiL.k Alliance +29.28%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.03%
#4 Biconomy Biconomy +23.68%
#5 THORChain THORChain +19.62%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +15.99%
#7 Moolah Moolah +14.27%
#8 THORChain Yield THORChain Yield +14.24%
#9 MetaDAO MetaDAO +12.22%
#10 Bless Bless +11.40%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Clasificación en acciones #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Precio por acción
$58.70
Última sincronización: 2024-01-23
Capitalización bursátil
$2.98B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Mirati Therapeutics, Inc. (MRTX)

Categoría

Healthcare
Ingresos de Mirati Therapeutics, Inc. (MRTX)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Mirati Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Mirati Therapeutics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH